Principal Financial Group Inc. Acquires Shares of 4,894 Iradimed Corporation (NASDAQ:IRMD)

Principal Financial Group Inc. purchased a new stake in Iradimed Corporation (NASDAQ:IRMD) during the third quarter, according to its most recent filing with the SEC. The firm purchased 4,894 shares of the medical equipment provider’s stock, valued at approximately $246,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Huntington National Bank grew its holdings in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 504 shares in the last quarter. Gladius Capital Management LP raised its stake in Iradimed by 126.6% in the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 965 shares during the period. Quantbot Technologies LP boosted its position in Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 1,052 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Iradimed during the third quarter worth approximately $126,000. Finally, SG Americas Securities LLC bought a new stake in Iradimed in the 3rd quarter valued at $147,000. 92.34% of the stock is owned by institutional investors.

Insider Transactions at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 37.10% of the company’s stock.

Iradimed Trading Up 1.7 %

NASDAQ IRMD opened at $56.49 on Tuesday. The company has a market cap of $715.90 million, a price-to-earnings ratio of 38.69 and a beta of 0.81. Iradimed Corporation has a 1-year low of $40.18 and a 1-year high of $57.95. The company has a 50 day moving average of $53.83 and a 200-day moving average of $49.30.

Iradimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were issued a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 annualized dividend and a dividend yield of 1.06%. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

Iradimed Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.